Oncology

SELECTIVE PROTEIN KINASE INHIBITORS TARGETING EPHA2

Oct 17, 2018

| Reference: 

B76157

  • novel EphA2 kinase inhibitors that borrow the chemical scaffold of the drug Dasatinib
  • higher selectivity compared to the existing non-designated alternatives l
  • less likely to be accompanied by side effects arising from off-target inhibition
Read more

HIGHLY ACTIVE AND SELECTIVE LIGANDS FOR INTEGRIN avß6

Oct 27, 2017

| Reference: 

B75165

  • Highly upregulated avß6 in different types of cancer
  • Peptides with remarkable affinity and high selctivity
  • No binding affinity toward other RGD-recognizing integrins
Read more

VSV/NDV HYBRID VIRUS CANCER THERAPY

Sep 3, 2018

| Reference: 

B75267

  • ‍VSV/NDV hybrid enables efficient tumor cell killing.
  • VSV/NDV hybrid virus effectively overcomes the safety concerns of each parental virus and
  • combines the advantages of both vesicular stomatitis virus (VSV) and Newcastle disease virus (NDV) vectors
Read more

NEW SEROTONIN RECEPTOR AGONISTS

Sep 16, 2017

| Reference: 

B72118

  • New serotonin receptor 5HT1P agonists (5-Benzyloxyindalpine, 5 BOIP) for the treatment or prevention of GI diseases such as constipation and functional dyspepsia and, in particular, for relieving GI symptoms
  • In the proximal stomach, 5BOIP evokes muscle relaxation, thereby improving the gastric accommodation reflex
  • 5 BOIP is highly specific, extremely stable against hydrolysis and oxidation and is much more convenient in production than other known agonists
Read more